Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012375 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT01012375 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 135 participants.
The verdict
NCT01012375, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
Interventions
- DRUG Placebo
- DRUG AZD1446
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012375
The ClinicalTrials.gov registry entry for NCT01012375 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01012375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01012375 about?
NCT01012375 is a clinical study titled "Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.". The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
What is the current status of trial NCT01012375?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2009-11. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01012375?
The interventions under investigation include: Placebo (DRUG), AZD1446 (DRUG).
Who is sponsoring clinical trial NCT01012375?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.